In a prospective trial assessing the effects of beta-blockers on sexual function men with coronary heart disease were randomized to a 4 month treatment with sustained release metoprolol 95 mg or placebo. A standardized and validated self-report questionnaire (KEED ¼ Kö lner Erhebungsbogen der Erektilen Dysfunktion) dealing with several aspects of sexual performance in men had to be answered at the beginning and at the end of the study. Based on 65 patients completing the study, sex life seemed unaffected by metoprolol treatment.
Introduction
Compliance with the prescribed medication is a key problem in all disciplines of medicine. Among other drugs, this holds true in particularly for betablockers in the treatment of coronary heart disease and hypertension. 1 Although proven beneficially in primary and secondary prevention, both, patients and even physicians tend to avoid the prescription of beta-blockers because of potential interference with their sex life. Beta-blockers seem to disturb the delicate balance between alpha-and beta-adrenergic nerve fibers. 2 However, it is surprising and unclear why not all or the majority of patients experience such side effects. In the following we report on a prospective, randomized and placebo controlled trial on the effect of beta-blockers on the sexual performance in men with coronary artery disease.
Methods
Consecutive male patients undergoing elective coronary angioplasty (PTCA) at Cologne University were asked to participate in a randomized and placebo controlled trial on the effect of beta-blockers on restenosis following PTCA and on the effect on erectile dysfunction. Pending a successful angioplasty, treatment with the study medication was continued for 4 months.
A total of 192 male patients were randomized to treatment with 95 mg sustained release metoprolol once a day or placebo beginning at least 1 day before PTCA. Pending a successful angioplasty and informed consent, patients received an anonymous and standardized questionnaire (KEED ¼ Kö lner Erhebungsbogen der Erektilen Dysfunktion) at study entry and after 4 months of treatment. The KEED is an 18-item questionnaire for the evaluation of erectile dysfunction, which has been developed and validated in German. 3, 4 It is aimed to identify symptoms of erectile dysfunction and its effects on quality of life. Questions 1 to 8 assess sociodemographic characteristics, medical history and medication, smoking and alcohol consumption habits. Questions 9 and 10 refer to sexual desire and frequency of sexual activities. Questions 11 to 16 assess erectile and orgasmic function on a 5-point scale, allowing calculation of an Erectile Dysfunction (ED) Score. Satisfaction with sex life and general well-being is covered by the last two questions. Apart from the standardized questionnaire a specific question at study end addressed the issue whether the study medication had affected sex life negatively, positively or not at all.
Patients with prior treatment using any betablocker within the last 12 months were considered inappropriate candidates for study participation. In addition, exclusion criteria for enrollment were cardiac conductance disturbances, presence of asthma or chronic obstructive lung disease.
Statistics
Statistical analysis was based on an intention-totreat analysis. However, both questionnaires were needed to evaluate the treatment effects of metoprolol and placebo on erectile dysfunction. Continuous data were presented as mean plus standard deviation (s.d.) and compared using student's t-test. Cross-tabulation was applied for categorical and numerical data. Covariance analysis was performed to assess the relevance of individual parameters. Statistics were calculated using the SPSS software.
Results
Of 192 randomized patients angioplasty was successful in 136 patients who continued taking the study medication and were asked to return for a control angiography after 4 months. Table 1 illustrates the breakdown of the fate of study participants.
Pending on a successful coronary angioplasty patients were asked to participate in a prospective and placebo controlled study on the effects of betablockers on erectile dysfunction. Of 50 patients in each treatment group at study entry a total of 38 patients in the metoprolol group and 27 in the placebo group completed both sets of questionnaires.
Baseline demographic data were tabulated in Table 2 . Most patients were in their 50s, married and retired from work. The frequency of sexual intercourse per month in the metoprolol group averaged to 6.8 AE 3.0 times at study entry and decreased not significantly to 6.0 AE 3.6 times at study end. In the placebo group the frequency decreased from 7.4 AE 4.6 times at study entry to 5.5 AE 3.6 at study end. All differences were statistically not significant when using Fischer's exact test.
Erectile Dysfunction (ED) scores were similar in the metoprolol and in the placebo group at study entry and did not changed significantly while taking the study medication (Table 4) . It is of note that about 60% of the study participants had no problems achieving a sufficient erection of their penis and reaching orgasm. According to specific questioning at study end most patients felt unaffected in their sex life by either metoprolol or placebo treatment (Table 3) .
Discussion
Beta-blockers have been gaining a key role in the treatment of various cardiovascular disorders. 5, 6 Apart from side effects predominantly affecting cardiac and lung function most patients are afraid of negative interference with their sex life while taking beta-blockers. 1 In the present prospective, randomized and placebo-controlled study patients in their fifties suffering from atherosclerotic heart disease were asked to evaluate their sexual performance before and after treatment with low dose beta-blockers or placebo. According to an anonymous standardized questionnaire questions dealing with various aspects of erectile dysfunction had to be answered at the beginning and at the end of the Beta-blockers and impotence D Franzen et al study. 3, 4 Overall, in this selected cohort success and frequency of the sexual intercourse seemed unaffected by metoprolol treatment.
In several other studies antihypertensive agents seem to exert a negative effect on the erectile function of the penis 7, 8 but the mechanisms involved remain unclear. It is of note that the prevalence of impotence in patients with vascular diseases and=or hypertension is far greater than in the average population and may be related to somatic and psychological factors. 9, 10 Our results are in agreement with studies in untreated hypertensive patients as compared to those treated with propanolol or other beta-blockers. 11, 12 Studies using various dosages of propanol showed that sexual dysfunction might be related to higher doses of betablocking agents. 13 The discrepancy of the effects of various betablockers and dosages may be related to a differential action on peripheral structures and=or on the central nervous system. 14 Apart from potential disadvantageous effects of the drop in blood pressure following beta-blocker treatment the local balance of alpha and beta-adrenergic function may be pertubated and interfer with the vascular events during erection. 2, 15, 16 According to the results of our study educational, social as well as psychological factors might play the dominant role in the development of impotence as has been indicated in other studies dealing with quality of life in patients with coronary heart disease. 1, 17 Further work is however needed to clarify the role of betablockers on the erectile function in different and larger populations.
